{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:05:38Z","timestamp":1794330338526,"version":"4.9.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This review addresses the challenges and advances in clinical endpoints for myositis, with a particular focus on ensuring comprehensive assessment of both muscle and skin disease activity. The relevance of this review stems from recent developments in outcome measures and their implications for clinical trial design and patient inclusivity. While quality of life (QoL) and lung involvement are also important aspects of myositis, they are beyond the scope of this review and need to be addressed in future studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Traditional outcome measures like the Total Improvement Score (TIS) have limitations, especially for patients with skin-predominant dermatomyositis (DM). Recent studies highlight the importance of incorporating skin-specific measures such as the Cutaneous Disease Area and Severity Index (CDASI) and the novel composite measure, Dermatomyositis Outcomes for Muscle and Skin (DMOMS). These measures provide a more balanced assessment of disease activity. Clinical trial data analyzed using these measures have demonstrated significant benefits for patients with both classic and amyopathic DM, emphasizing the need for their broader adoption.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Advancements in outcome measures are crucial for inclusive and effective myositis clinical trials. Incorporating comprehensive tools like the DMOMS can enhance the assessment of both muscle and skin disease activities, potentially leading to better therapeutic strategies and improved patient outcomes. This shift is essential for addressing the needs of all Idiopathic inflammatory myopathy patients, including those with skin-predominant DM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001044","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T01:53:08Z","timestamp":1724377988000},"page":"430-437","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Clinical endpoints in myositis: challenges and ways forward"],"prefix":"10.1097","volume":"36","author":[{"given":"Cristina","family":"Ricco","sequence":"first","affiliation":[{"name":"Corporal Michael J. Crescenz VA Medical Center"},{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Stone","sequence":"additional","affiliation":[{"name":"Corporal Michael J. Crescenz VA Medical Center"},{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[{"name":"Corporal Michael J. Crescenz VA Medical Center"},{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/ITT.S381472","article-title":"Dermatomyositis: practical guidance and unmet needs","volume":"13","author":"Cassard","year":"2024","journal-title":"Immunotargets Ther"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7861\/clinmedicine.17-4-322","article-title":"Idiopathic inflammatory myopathies \u2013 a guide to subtypes, diagnostic approach and treatment","volume":"17","author":"Oldroyd","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1136\/annrheumdis-2020-219426","article-title":"Correspondence on \u2019EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups\u2019","volume":"82","author":"Mohammad","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/1756-185X.13605","article-title":"Validation of 2017 classification criteria for adult and juvenile idiopathic inflammatory myopathies proposed by EULAR\/ACR in Chinese patients","volume":"22","author":"Zhang","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"688","DOI":"10.55563\/clinexprheumatol\/4tz6ci","article-title":"Validation of the EULAR\/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients","volume":"39","author":"Sag","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1136\/annrheumdis-2017-212774","article-title":"Performance of the 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice","volume":"77","author":"Ho\u010devar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/bjd.17536","article-title":"The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria","volume":"180","author":"Concha","year":"2019","journal-title":"Br J Dermatol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","article-title":"Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease","volume":"79","author":"Patel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3899\/jrheum.161183","article-title":"Muscle strength and muscle endurance during the first year of treatment of polymyositis and dermatomyositis: a prospective study","volume":"45","author":"Alexanderson","year":"2018","journal-title":"J Rheumatol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0889-857X(05)70350-1","article-title":"Classification and treatment of the juvenile idiopathic inflammatory myopathies","volume":"23","author":"Rider","year":"1997","journal-title":"Rheum Dis Clin North Am"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12969-023-00844-5","article-title":"Currently recommended skin scores correlate highly in the assessment of patients with Juvenile Dermatomyositis (JDM)","volume":"21","author":"Gebreamlak","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mus.26307","article-title":"Muscle endurance deficits in myositis patients despite normal manual muscle testing scores","volume":"59","author":"Amici","year":"2019","journal-title":"Muscle Nerve"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3899\/jrheum.191374","article-title":"Functional Index-3: a valid and reliable functional outcome assessment measure in patients with dermatomyositis and polymyositis","volume":"48","author":"Ernste","year":"2021","journal-title":"J Rheumatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11926-012-0249-3","article-title":"Morbidity and mortality in adult polymyositis and dermatomyositis","volume":"14","author":"Marie","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.15278","article-title":"Expanding the use of the Cutaneous Dermatomyositis Area and Severity Index (CDASI) to nondermatologists","volume":"176","author":"Kurtzman","year":"2017","journal-title":"Br J Dermatol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jaad.2017.10.022","article-title":"Cutaneous dermatomyositis disease course followed over time using the Cutaneous Dermatomyositis Disease Area and Severity Index","volume":"79","author":"Chansky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1365-2133.2009.09521.x","article-title":"Modification of the cutaneous dermatomyositis disease area and severity index, an outcome instrument","volume":"162","author":"Yassaee","year":"2010","journal-title":"Br J Dermatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"102234","DOI":"10.1016\/j.eclinm.2023.102234","article-title":"Efficacy of intravenous immunoglobulins (IVIg) in improving skin symptoms in patients with dermatomyositis: a posthoc analysis of the ProDERM study","volume":"64","author":"Werth","year":"2023","journal-title":"EClinicalMedicine"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjd.15140","article-title":"The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists","volume":"176","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1553-2712.2000.tb02249.x","article-title":"Research fundamentals: selection and development of clinical outcome measures","volume":"7","author":"Singer","year":"2000","journal-title":"Acad Emerg Med"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2133.2007.08342.x","article-title":"Development and validation of the Dermatomyositis Skin Severity Index","volume":"158","author":"Carroll","year":"2008","journal-title":"Br J Dermatol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b3 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"103334","DOI":"10.1016\/j.autrev.2023.103334","article-title":"The interferon in idiopathic inflammatory myopathies: different signatures and new therapeutic perspectives. A literature review","volume":"22","author":"Gasparotto","year":"2023","journal-title":"Autoimmun Rev"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1056\/NEJMc2214285","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"388","author":"Werth","year":"2023","journal-title":"N Engl J Med"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11926-019-0862-5","article-title":"Patient-reported outcomes in adult idiopathic inflammatory myopathies","volume":"21","author":"DiRenzo","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"152111","DOI":"10.1016\/j.semarthrit.2022.152111","article-title":"Reliability and validity of PROMIS physical function, pain interference, and fatigue as patient reported outcome measures in adult idiopathic inflammatory myopathies: International study from the OMERACT myositis working group","volume":"58","author":"DiRenzo","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaad.2022.03.054","article-title":"Preliminary definition of cutaneous flare in dermatomyositis: a retrospective review","volume":"88","author":"Dan","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatol Clin"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/bjd\/ljad133","article-title":"A comparison of the efficacy of Skindex-16 and Skindex-29 in dermatomyositis","volume":"189","author":"Dan","year":"2023","journal-title":"Br J Dermatol"},{"issue":"(suppl 9)","key":"R41-20250526","article-title":"Impact of photosensitivity on quality of life in dermatomyositis [abstract]","volume":"75","author":"Gebre","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R42-20250526","article-title":"A Revised outcome measure for dermatomyositis clinical trials: the dermatomyositis outcomes for muscle and skin (DMOMS)","author":"Pandya","year":"2023","journal-title":"Am Coll Rheumatol: Arthritis Rheumatol"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"(Suppl 1)","key":"R44-20250526","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/annrheumdis-2022-eular.5037","article-title":"OP0162 efficacy and safety of lenabasum in the phase 3 determine trial in dermatomyositis","volume":"81","author":"Werth","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jid.2023.05.025","article-title":"Validation of cutaneous dermatomyositis disease area and severity index activity score and other efficacy outcomes as measures of skin disease in dermatomyositis in the lenabasum phase 3 trial","volume":"143","author":"Pandya","year":"2023","journal-title":"J Invest Dermatol"},{"issue":"(suppl 9)","key":"R46-20250526","article-title":"Cutaneous manifestations, clinical trials, safety efficacy and safety of lenabasum in the phase 3 DeterMine trial in dermatomyositis [abstract]","volume":"74","author":"Werth","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"(8, Supplement)","key":"R47-20250526","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jid.2024.06.157","article-title":"Classification criteria for cutaneous dermatomyositis: A validation study","volume":"144","author":"Lim","year":"2024","journal-title":"J Invest Dermatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:18:33Z","timestamp":1748294313000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001044","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}